The S&P 500 index scored its 68th record close of the year Thursday, ahead of the long Christmas holiday weekend, on optimism that the omicron variant of COVID won’t derail global economies.
Investors also were absorbing a relatively benign batch of U.S. data, including inflation, durable goods orders and jobless benefit claims published Thursday.
How did stock indexes trade?
- The Dow Jones Industrial Average DJIA rose 196.67 points, or 0.6%, to end at 35,950.56.
- The S&P 500 SPX advanced 29.23 points, or 0.6%, closing at a record 4,725.79, eclipsing its prior record close of 4,712.02 set on Dec. 10.
- The Nasdaq Composite COMP gained 131.48 points, or 0.9%, to finish at 15,653.37.
On Wednesday, major indexes scored gains. For the week ending Thursday, the Dow rose 1.7%, the S&P 500 gained 2.3%, and the Nasdaq advanced 3.2%.
What drove markets?
Stocks have climbed for two of the past three weeks, but on lower trading volumes this week ahead of the long holiday weekend, with Wall Street closed on Friday, Christmas Eve.
“Today, it is about economic optimism that this variant is not going to be as bad as delta and original virus,” said Kent Engelke, chief economic strategist at Capitol Securities Management, in a phone interview.
Engelke also said sentiment on Wall Street improved following reassurances this week from the White House that no 2020-style lockdowns were on the table as part of its plan to fight the coronavirus’ omicron variant.
“But it is economic optimism on light volume,” he said.
The next week will see business as usual, albeit in likely continued thin trading. U.S. markets won’t close either Friday, Dec. 31, or Monday, Jan. 3, 2022, in observation of the New Year’s holiday, though other global markets will.
Investors were digesting a fresh batch of U.S. data Thursday.
First-time jobless claims were unchanged at 205,000 in the week ended Dec. 18, while consumer spending and personal spending nudged higher, the 12-month PCE inflation indicator rose 5.7% in November. Durable goods orders rose 2.5% for the month.
“The data added to evidence that holiday spending was likely pulled forward into October,” Pooja Sriram, from Barclay’s U.S. economic research team, wrote in a note following the consumer data.
The University of Michigan’s gauge of consumer sentiment rose slightly to a final December reading of 70.6 from the initial figure of 70.4. U.S. new home sales jumped 12.4% to a seasonally-adjusted annual rate of 744,000 in November from a revised 662,000 in the prior month, the government reported Thursday, but came in below expectations for an annual rate of 766,000.
“After a work-from-home rise and fall, home sales seem to have stabilized toward a moderate growth trajectory,” U.S. economists at Mizuho wrote, in a client note. “It also demonstrates that despite rising prices for goods and assets, households are still making large purchases.”
Adding to the positive newsflow, AstraZeneca AZN UK:AZN said Thursday that its COVID-19 booster shot was effective against the highly contagious variant, in a laboratory study.
A pair of U.K. studies released Wednesday also showed the omicron variant may be milder than the delta one, while South African medical experts have suggested the surge in cases may have peaked, with fewer hospitalizations and severe illness.
“The caveat here is that even if omicron is less dangerous, the fact that it is so much more transmissible means that health services are still at risk of being overwhelmed by the surge in new infections,” said Raffi Boyadjian, lead investment analyst at XM, in a note to clients.
New York City’s Times Square New Year’s Eve celebration plans were scaled back Thursday by mayor Bill de Blasio, as the city grapples with surging COVID-19 infections that nationally have led to canceled holiday parties, concerts and sporting events.
With central banks such as the Fed slowly turning off the stimulus taps and President Biden’s $1.75 trillion spending bill hanging in the balance, it probably won’t take much to spark another panic in the markets, Boyadjian added. But for now, stocks globally are enjoying another positive day, led by strong gains in Asia and a solid open in Europe, he said.
What companies were in focus?
- The Food and Drug Administration on Thursday granted emergency use authorization to Merck & Co. Inc.’s MRK antiviral drug for high-risk adults over the age of 18. Shares fell 0.6%.
- Shares of Novavax NVAX fell 3.3% after the biotech company said an early study data of its COVID-19 vaccine booster showed immune responses against the omicron variant.
- Shares of Ortho Clinical Diagnostics OCDX gained 6.9% after diagnostic healthcare products maker Quidel said it would buy the in vitro diagnostics company in a $6 billion cash and stock deal.
- JD.com shares JD tumbled 6.9% after Tencent said it will substantially reduce its stake in the Chinese internet company.
How did other assets trade?
- The yield on the 10-year Treasury note BX:TMUBMUSD10Y rose 3.5 basis points to 1.492%, advancing 9.1 basis points in the holiday week. Yields and debt prices move opposite each other.
- The ICE U.S. Dollar Index DXY, a measure of the currency against a basket of six major rivals, was 0.1% lower.
- Oil futures closed higher, with the U.S. benchmark CL00 up 1.4%, ending at $73.79 a barrel, while gold futures GC00 closed up 0.5% to settle at $1,811.70 an ounce.
- Bitcoin BTCUSD gained 4%.
- The Stoxx Europe 600 index XX:SXXP closed 1% higher and London’s FTSE 100 UK:UKX gained 0.4%.
- The Shanghai Composite CN:SHCOMP rose 0.9%, while the Hang Seng Index HK:HSI gained 0.3% and Japan’s Nikkei 225 JP:NIK jumped 0.8%.